INSMED Inc (INSM)
Data as of , from SEC Form 4 filings.
See up to 3 months of INSM. The 7-day demo opens the 1M and 3M ranges and puts INSM on your watchlist.
Start 7-day demoLatest INSM insider trades
About INSMED Inc (INSM)
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
- BRIDGEWATER, NJ
- 1,664
- 2000
- XNAS
INSM Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 7 | 307,723 | $40.33M |
| Option exercise | 14 | 555,446 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
INSM insider transactions (Form 4)
78121 Form 4 filings on record, the earliest from Dec 13, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David R. Brennan - Director | Open-market sale | Common Stock | 25,000 | $124.00 | $3.10M | |
| Open-market sale | Common Stock | 5,000 | $127.53 footnote F1 | $638K | ||
| ||||||
| Option exercise | Common Stock | 82,280 | $13.67 | $1.12M | ||
| Option exercise | Common Stock | 76,600 | $17.16 | $1.31M | ||
| Option exercise | Common Stock | 80,970 | $30.46 | $2.47M | ||
| Open-market sale | Common Stock | 239,850 | $133.27 footnote F2 | $31.96M | ||
| Option exercise | Stock Option (right to buy) | 82,280 | $0.00 | - | ||
| Option exercise | Stock Option (right to buy) | 76,600 | $0.00 | - | ||
| Option exercise | Stock Option (right to buy) | 80,970 | $0.00 | - | ||
| ||||||
| Martina M.D. Flammer - Officer | Option exercise | Common Stock | 18,278 | $18.95 | $346K | |
| Martina M.D. Flammer - Officer | Option exercise | Common Stock | 8,895 | $25.83 | $230K | |
| Martina M.D. Flammer - Officer | Open-market sale | Common Stock | 8,895 | $127.00 | $1.13M | |
| Martina M.D. Flammer - Officer | Open-market sale | Common Stock | 18,278 | $129.40 footnote F2 | $2.37M | |
| Martina M.D. Flammer - Officer | Option exercise | Stock Option (right to buy) | 18,278 | $0.00 | - | |
| Martina M.D. Flammer - Officer | Option exercise | Stock Option (right to buy) | 8,895 | $0.00 | - | |
| ||||||
| Option exercise | Common Stock | 6,260 | $30.46 | $191K | ||
| Option exercise | Common Stock | 4,440 | $17.16 | $76K | ||
| Open-market sale | Common Stock | 4,828 | $105.62 footnote F2 | $510K | ||
| Open-market sale | Common Stock | 5,872 | $106.43 footnote F3 | $625K | ||
| Option exercise | Stock Option (right to buy) | 6,260 | $0.00 | - | ||
| Option exercise | Stock Option (right to buy) | 4,440 | $0.00 | - | ||
| ||||||
| Option exercise | Common Stock | 6,259 | $30.46 | $191K | ||
| Option exercise | Common Stock | 4,440 | $17.16 | $76K | ||
| Open-market sale | Common Stock | 5,005 | $116.55 footnote F3 | $583K | ||
| Open-market sale | Common Stock | 2,335 | $117.62 footnote F4 | $275K | ||
| Open-market sale | Common Stock | 3,359 | $118.52 footnote F5 | $398K | ||
| Option exercise | Stock Option (right to buy) | 6,259 | $0.00 | - | ||
| Option exercise | Stock Option (right to buy) | 4,440 | $0.00 | - | ||
| ||||||
| Martina M.D. Flammer - Officer | Option exercise | Common Stock | 7,945 | $29.13 | $231K | |
| Martina M.D. Flammer - Officer | Option exercise | Common Stock | 4,357 | $19.74 | $86K | |
| Martina M.D. Flammer - Officer | Open-market sale | Common Stock | 4,854 | $109.02 footnote F2 | $529K | |
| Martina M.D. Flammer - Officer | Open-market sale | Common Stock | 7,448 | $110.60 footnote F3 | $824K | |
| Martina M.D. Flammer - Officer | Option exercise | Stock Option (right to buy) | 7,945 | $0.00 | - | |
| Martina M.D. Flammer - Officer | Option exercise | Stock Option (right to buy) | 4,357 | $0.00 | - | |
| ||||||
| Open-market sale | Common Stock | 3,723 | $104.28 footnote F4 | $388K | ||
| Open-market sale | Common Stock | 2,456 | $105.27 footnote F5 | $259K | ||
| Open-market sale | Common Stock | 1,292 | $106.27 footnote F6 | $137K | ||
| Option exercise | Stock Option (right to buy) | 12,518 | $0.00 | - | ||
| Option exercise | Stock Option (right to buy) | 8,880 | $0.00 | - | ||
| Option exercise | Common Stock | 12,518 | $30.46 | $381K | ||
| Option exercise | Common Stock | 8,880 | $17.16 | $152K | ||
| Open-market sale | Common Stock | 12,091 | $102.34 footnote F2 | $1.24M | ||
| Open-market sale | Common Stock | 1,836 | $103.10 footnote F3 | $189K | ||
| ||||||
| Samuele Butera - Officer | Grant or award | Common Stock | 7,342 footnote F1 | - footnote F2 | - | |
| Samuele Butera - Officer | Grant or award | Stock Option (right to buy) | 12,570 | $0.00 | - | |
| ||||||
| Michael Alexander Smith - Officer | Open-market sale | Common Stock | 1,806 | $95.82 | $173K | |
| Open-market sale | Common Stock | 6,515 | $94.03 | $613K | ||
| Open-market sale | Common Stock | 2,370 | $102.27 | $242K | ||
| Sara Bonstein - Officer | Open-market sale | Common Stock | 2,404 | $102.27 | $246K | |
| Michael Alexander Smith - Officer | Open-market sale | Common Stock | 2,159 | $102.27 | $221K | |
| Open-market sale | Common Stock | 7,605 | $102.27 | $778K | ||
| Martina M.D. Flammer - Officer | Open-market sale | Common Stock | 2,566 | $102.27 | $262K | |
| Martina M.D. Flammer - Officer | Open-market sale | Common Stock | 1,858 | $103.78 | $193K | |
| Michael Alexander Smith - Officer | Open-market sale | Common Stock | 6,149 | $108.47 | $667K | |
| Option exercise | Common Stock | 6,259 | $30.46 | $191K | ||
| Option exercise | Common Stock | 4,440 | $17.16 | $76K | ||
| Open-market sale | Common Stock | 5,753 | $105.32 footnote F2 | $606K | ||
| Open-market sale | Common Stock | 11,836 | $106.39 footnote F3 | $1.26M | ||
| Open-market sale | Common Stock | 7,975 | $106.97 footnote F4 | $853K | ||
| Option exercise | Stock Option (right to buy) | 6,259 | $0.00 | - | ||
| Option exercise | Stock Option (right to buy) | 4,440 | $0.00 | - | ||
| ||||||
| Sara Bonstein - Officer | Open-market sale | Common Stock | 8,272 | $116.18 | $961K | |
| Carol Schafer - Director | Grant or award | Common Stock | 3,305 footnote F1 | - footnote F2 | - | |
| ||||||
| Open-market sale | Common Stock | 5,837 | $116.18 | $678K | ||
| Elizabeth M. Anderson - Director | Grant or award | Common Stock | 3,305 footnote F1 | - footnote F2 | - | |
| ||||||
| Martina M.D. Flammer - Officer | Open-market sale | Common Stock | 4,470 | $112.76 footnote F2 | $504K | |
| Martina M.D. Flammer - Officer | Open-market sale | Common Stock | 3,384 | $116.18 | $393K | |
| Martina M.D. Flammer - Officer | Open-market sale | Common Stock | 10,479 | $117.54 | $1.23M | |
| ||||||
| Michael Alexander Smith - Officer | Open-market sale | Common Stock | 4,109 | $116.18 | $477K | |
| Grant or award | Common Stock | 3,305 footnote F1 | - footnote F2 | - | ||
| ||||||
| David R. Brennan - Director | Grant or award | Common Stock | 3,305 footnote F1 | - footnote F2 | - | |
| ||||||
| Clarissa Desjardins - Director | Grant or award | Common Stock | 3,305 footnote F1 | - footnote F2 | - | |
| ||||||
| Leo Lee - Director | Grant or award | Common Stock | 3,305 footnote F1 | - footnote F2 | - | |
| ||||||
| Open-market sale | Common Stock | 13,283 | $116.18 | $1.54M | ||
| Martina M.D. Flammer - Officer | Option exercise | Common Stock | 12,949 | $17.07 | $221K | |
| Martina M.D. Flammer - Officer | Open-market sale | Common Stock | 12,119 | $100.35 footnote F2 | $1.22M | |
| Martina M.D. Flammer - Officer | Open-market sale | Common Stock | 830 | $101.18 footnote F3 | $84K | |
| Martina M.D. Flammer - Officer | Option exercise | Stock Option (right to buy) | 12,949 | $0.00 | - | |
| ||||||
Recent INSM Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Brennan David R | Director | 25,000 | $3.10M | View on EDGAR | |
| MELVIN SHAROKY | Director | 5,000 | $638K | View on EDGAR | |
| Roger Adsett | Officer | 239,850 | $31.96M | View on EDGAR |
Stock trades in INSM disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.
| Member | Type | Traded | Disclosed | Value range | Owner | Days to disclose | Filing |
|---|---|---|---|---|---|---|---|
| Sale (partial) | $1,001 to $15,000 | Joint | 27 days | Original filing | |||
| Sale | $1,001 to $15,000 | Member | 46 daysLate | Original filing |
House of Representatives Periodic Transaction Reports from 2024. Senate filings are not included yet. The full history of INSM beside its insider purchases is in the Congress Tracker.
INSM insider trading FAQ
What is the latest insider trade for INSM?
INSMED Inc (INSM) had 5 insider filings in the last 90 days, with the most recent on 2026-09-11. The full record for INSM runs to 121 Form 4 filings, the earliest from 2024-12-13. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying INSM stock?
No insider purchases of INSM were filed in the last 90 days. 2 purchases are on record for this company.
How many insiders are selling INSM stock?
7 insider sales of INSM were filed in the last 90 days, totaling $40.33M.
Where can I see INSM SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects INSM Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - David R. Brennan view on EDGAR
- - Melvin Md Sharoky view on EDGAR
- - Roger Adsett view on EDGAR
- - Martina M.D. Flammer view on EDGAR
- - William Lewis view on EDGAR
- - William Lewis view on EDGAR
- - Martina M.D. Flammer view on EDGAR
- - William Lewis view on EDGAR
- - Samuele Butera view on EDGAR
- - Michael Alexander Smith view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where INSM's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow INSM with a 7-day demo
- INSM on your watchlist
- Every INSM Form 4 filing on record
- Up to 3 months of INSM price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive